Results 181 to 190 of about 5,420 (200)

Elvitegravir

2017
openaire   +1 more source

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV

Expert Review of Anti-Infective Therapy, 2017
Daniel Podzamczer, Arkaitz Imaz
exaly  

Cobicistat/elvitegravir/dolutegravir/raltegravir

Reactions Weekly, 2018
openaire   +1 more source

Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV

Annals of Pharmacotherapy, 2019
Christine Hughes, Michelle M Foisy
exaly  

Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults

Expert Opinion on Pharmacotherapy, 2016
Stefano Bonora, Alice Trentalange, Andrea Calcagno   +2 more
exaly  

ELVITEGRAVIR / COBICISTAT /

2015
openaire   +1 more source

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV‐infected patients in clinical practice: results from a multicentre, observational study

HIV Medicine, 2019
Arturo Ciccullo, Giordano Madeddu, Stefano Rusconi   +2 more
exaly  

Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide

Reactions weekly

semanticscholar   +1 more source

Cobicistat/elvitegravir/emtricitabine/tenofovir

Reactions Weekly, 2016
openaire   +1 more source

Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients

HIV Clinical Trials, 2014
Michael Abram, Kirsten White, Andrew Cheng   +2 more
exaly